4 results on '"Sarah Pedretti"'
Search Results
2. Dose Dependent Antimicrobial Cellular Cytotoxicity—Implications for ex vivo Diagnostics
- Author
-
Ana Copaescu, Phuti Choshi, Sarah Pedretti, Effie Mouhtouris, Jonathan Peter, and Jason A. Trubiano
- Subjects
delayed hypersensitivity reaction ,drug allergy ,severe cutaneous adverse reaction ,T-cell ,enzyme linked ImmunoSpot ,cytotoxicity ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Introduction:Ex vivo and in vitro diagnostics, such as interferon-γ (IFN-γ) release enzyme linked ImmunoSpot (ELISpot) and flow cytometry, are increasingly employed in the research and diagnostic setting for severe T-cell mediated hypersensitivity. Despite an increasing use of IFN-γ release ELISpot for drug causality assessment and utilization of a range of antimicrobial concentrations ex vivo, data regarding antimicrobial-associated cellular cytotoxicity and implications for assay performance remain scarcely described in the literature. Using the measurement of lactate dehydrogenase (LDH) and the 7-AAD cell viability staining, we aimed via an exploratory study, to determine the maximal antimicrobial concentrations required to preserve cell viability for commonly implicated antimicrobials in severe T-cell mediated hypersensitivity.Method: After an 18-h incubation of patient peripheral blood monocytes (PBMCs) and antimicrobials at varying drug concentrations, the cell cytotoxicity was measured in two ways. A colorimetric based assay that detects LDH activity and by flow cytometry using the 7-AAD cell viability staining. We used the PBMCs collected from three healthy control participants with no known history of adverse drug reaction and two patients with a rifampicin-associated drug reaction with eosinophilia and systemic symptoms (DRESS), confirmed on IFN-γ ELISpot assay. The PBMCs were stimulated for the investigated drugs at the previously published drug maximum concentration (Cmax), and concentrations 10- and 100-fold above.Results: In a human immunodeficiency virus (HIV) negative and a positive rifampicin-associated DRESS with positive ex vivo IFN-γ ELISpot assay, use of 10- and 100-fold Cmax drug concentrations decreased spot forming units/million cells by 32–100%, and this corresponded to cell cytotoxicity of more than 40 and 20% using an LDH assay and 7-AAD cell viability staining, respectively. The other antimicrobials (ceftriaxone, flucloxacillin, piperacillin/tazobactam, and isoniazid) tested in healthy controls showed similar dose-dependent increased cytotoxicity using the LDH assay, but cytotoxicity remained lower than 40% for all Cmax and 10-fold Cmax drug concentrations except flucloxacillin. All 100-fold Cmax concentrations resulted in cell death >40% (median 57%), except for isoniazid. 7-AAD cell viability staining also confirmed an increase in lymphocyte death in PBMCs incubated with 10-fold and 100-fold above Cmax for ceftriaxone, and flucloxacillin; however, piperacillin/tazobactam and isoniazid indicated no differences in percentages of viable lymphocytes across concentrations tested.Conclusion: The LDH cytotoxicity and 7-AAD cell viability staining techniques both demonstrate increased cell death corresponding to a loss in ELISpot sensitivity, with use of higher antimicrobial drug concentrations for ex vivo diagnostic IFN-γ ELISpot assays. For all the antimicrobials evaluated, the use of Cmax and 10-fold Cmax concentrations impacts cell viability and potentially affects ELISpot performance. These findings inform future approaches for ex vivo diagnostics such as IFN-γ release ELISpot.
- Published
- 2021
- Full Text
- View/download PDF
3. Pharmacological Intervention to Modulate HDL: What Do We Target?
- Author
-
Nicholas J. Woudberg, Sarah Pedretti, Sandrine Lecour, Rainer Schulz, Nicolas Vuilleumier, Richard W. James, and Miguel A. Frias
- Subjects
HDL ,pharmaceutical intervention ,HDL functionality ,HDL subclass ,cardiovascular disease ,Therapeutics. Pharmacology ,RM1-950 - Abstract
The cholesterol concentrations of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) have traditionally served as risk factors for cardiovascular disease. As such, novel therapeutic interventions aiming to raise HDL cholesterol have been tested in the clinical setting. However, most trials led to a significant increase in HDL cholesterol with no improvement in cardiovascular events. The complexity of the HDL particle, which exerts multiple physiological functions and is comprised of a number of subclasses, has raised the question as to whether there should be more focus on HDL subclass and function rather than cholesterol quantity. We review current data regarding HDL subclasses and subclass-specific functionality and highlight how current lipid modifying drugs such as statins, cholesteryl ester transfer protein inhibitors, fibrates and niacin often increase cholesterol concentrations of specific HDL subclasses. In addition this review sets out arguments suggesting that the HDL3 subclass may provide better protective effects than HDL2.
- Published
- 2018
- Full Text
- View/download PDF
4. Pharmacological Intervention to Modulate HDL: What Do We Target?
- Author
-
Miguel Frias, Sandrine Lecour, Sarah Pedretti, Nicolas Vuilleumier, Rainer Schulz, Nicholas J. Woudberg, and Richard W. James
- Subjects
0301 basic medicine ,HDL functionality ,HDL ,Disease ,Review ,030204 cardiovascular system & hematology ,Pharmacology ,Subclass ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,pharmaceutical intervention ,cardiovascular disease ,Cholesterylester transfer protein ,Medicine ,Pharmacology (medical) ,Hdl functionality ,HDL particle ,ddc:576 ,ddc:616 ,biology ,business.industry ,Cholesterol ,lcsh:RM1-950 ,nutritional and metabolic diseases ,lcsh:Therapeutics. Pharmacology ,030104 developmental biology ,chemistry ,HDL subclass ,biology.protein ,lipids (amino acids, peptides, and proteins) ,business ,Niacin ,Lipoprotein - Abstract
The cholesterol concentrations of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) have traditionally served as risk factors for cardiovascular disease. As such, novel therapeutic interventions aiming to raise HDL cholesterol have been tested in the clinical setting. However, most trials led to a significant increase in HDL cholesterol with no improvement in cardiovascular events. The complexity of the HDL particle, which exerts multiple physiological functions and is comprised of a number of subclasses, has raised the question as to whether there should be more focus on HDL subclass and function rather than cholesterol quantity. We review current data regarding HDL subclasses and subclass-specific functionality and highlight how current lipid modifying drugs such as statins, cholesteryl ester transfer protein inhibitors, fibrates and niacin often increase cholesterol concentrations of specific HDL subclasses. In addition this review sets out arguments suggesting that the HDL3 subclass may provide better protective effects than HDL2.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.